Journal Article
. 2007 Dec;100(1).
doi: 10.1093/jnci/djm267.

Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study

Lisbeth Bertelsen 1 Leslie Bernstein  Jørgen H Olsen  Lene Mellemkjaer  Robert W Haile  Charles F Lynch  Kathleen E Malone  Hoda Anton-Culver  Jane Christensen  Bryan Langholz  Duncan C Thomas  Colin B Begg  Marinela Capanu  Bent Ejlertsen  Marilyn Stovall  John D Boice  Roy E Shore  Women's Environment, Cancer and Radiation Epidemiology Study Collaborative Group  Jonine L Bernstein  
Affiliations
  • PMID: 18159070
  •     38 citations

Abstract

Background: Results from randomized trials indicate that treatment with tamoxifen or chemotherapy for primary breast cancer reduces the risk for contralateral breast cancer. However, less is known about how long the risk is reduced and the impact of factors such as age and menopausal status.

Methods: The study included 634 women with contralateral breast cancer (case patients) and 1158 women with unilateral breast cancer (control subjects) from the Women's Environment, Cancer and Radiation Epidemiology Study. The women were younger than age 55 when they were first diagnosed with breast cancer during 1985-1999. Rate ratios (RRs) and 95% confidence intervals (CIs) for contralateral breast cancer after treatment with chemotherapy or tamoxifen were assessed by multivariable adjusted conditional logistic regression analyses.

Results: Chemotherapy was associated with a lower risk for contralateral breast cancer (RR = 0.57, 95% CI = 0.42 to 0.75) than no chemotherapy. A statistically significant association between chemotherapy and reduced risk for contralateral breast cancer persisted up to 10 years after the first breast cancer diagnosis and was stronger among women who became postmenopausal within 1 year of the first breast cancer diagnosis (RR = 0.28, 95% CI = 0.11 to 0.76). Tamoxifen use was also associated with reduced risk for contralateral breast cancer (RR = 0.66, 95% CI = 0.50 to 0.88) compared with no use, and the association was statistically significant for 5 years after the first diagnosis.

Conclusion: The associations between chemotherapy and tamoxifen treatment and reduced risk for contralateral breast cancer appear to continue for 10 and 5 years, respectively, after the initial breast cancer is diagnosed. Ovarian suppression may have a role in the association between chemotherapy and reduced risk for contralateral breast cancer.

What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?
Michaela J Higgins, Nancy E Davidson.
Curr Oncol Rep, 2008 Dec 17; 11(1). PMID: 19080741
Review.
Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: The Women's Environmental Cancer and Radiation Epidemiology Study.
Julia A Knight, Leslie Bernstein, +11 authors, Jonine L Bernstein.
Am J Epidemiol, 2009 Feb 13; 169(8). PMID: 19211621    Free PMC article.
Relation of risk of contralateral breast cancer to the interval since the first primary tumour.
C Rubino, R Arriagada, S Delaloge, M G Lê.
Br J Cancer, 2009 Nov 19; 102(1). PMID: 19920826    Free PMC article.
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Kerryn W Reding, Jonine L Bernstein, +16 authors, WECARE Collaborative Study Group.
Breast Cancer Res Treat, 2010 Feb 06; 123(2). PMID: 20135344    Free PMC article.
Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study.
Jonine L Bernstein, Robert W Haile, +20 authors, WECARE Study Collaborative Group.
J Natl Cancer Inst, 2010 Mar 23; 102(7). PMID: 20305132    Free PMC article.
Body mass index and risk of second primary breast cancer: the WECARE Study.
Jennifer D Brooks, Esther M John, +9 authors, Leslie Bernstein.
Breast Cancer Res Treat, 2011 Sep 06; 131(2). PMID: 21892703    Free PMC article.
Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study.
Jennifer D Brooks, Sharon N Teraoka, +17 authors, Jonine L Bernstein.
Hum Mutat, 2011 Sep 08; 33(1). PMID: 21898661    Free PMC article.
Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study.
Sharon N Teraoka, Jonine L Bernstein, +17 authors, Patrick Concannon.
Breast Cancer Res, 2011 Nov 18; 13(6). PMID: 22087758    Free PMC article.
Options for early breast cancer follow-up in primary and secondary care - a systematic review.
Frances Taggart, Peter Donnelly, Janet Dunn.
BMC Cancer, 2012 Jun 15; 12. PMID: 22695275    Free PMC article.
Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.
Jennifer D Brooks, Sharon N Teraoka, +12 authors, Jane C Figueiredo.
Int J Mol Epidemiol Genet, 2013 Apr 09; 4(1). PMID: 23565321    Free PMC article.
Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.
Jennifer D Brooks, Sharon N Teraoka, +11 authors, Jane C Figueiredo.
Cancer Causes Control, 2013 Jun 19; 24(8). PMID: 23775025    Free PMC article.
Effect of taxane-based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated by 3T MR.
Jeon-Hor Chen, Wei-Fan Pan, +9 authors, Min-Ying Su.
NMR Biomed, 2013 Aug 14; 26(12). PMID: 23940080    Free PMC article.
The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?
Stephen R D Johnston, Belinda Yeo.
Curr Oncol Rep, 2014 Jan 07; 16(1). PMID: 24390724
Review.
Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.
M Kriege, A Hollestelle, +9 authors, C Seynaeve.
Br J Cancer, 2014 Jun 12; 111(5). PMID: 24918820    Free PMC article.
Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis.
Oluwadamilola Motunaryo Fayanju, Carolyn R T Stoll, +2 authors, Julie A Margenthaler.
Ann Surg, 2014 Jun 21; 260(6). PMID: 24950272    Free PMC article.
Systematic Review.
Metabolic syndrome and outcomes following early-stage breast cancer.
Gregory S Calip, Kathleen E Malone, +3 authors, Denise M Boudreau.
Breast Cancer Res Treat, 2014 Oct 11; 148(2). PMID: 25301086    Free PMC article.
Women with endometriosis have a higher DNA repair capacity and diminished breast cancer risk.
Jaime L Matta, Idhaliz Flores, +3 authors, Manuel Bayona.
Mol Cancer Biol, 2014 Dec 05; 1(1). PMID: 25473592    Free PMC article.
Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry.
Julia Prater, Fabio Valeri, +2 authors, Silvia Dehler.
J Cancer Res Clin Oncol, 2015 Aug 25; 142(2). PMID: 26298838
Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
Sara Alkner, Pär-Ola Bendahl, +3 authors, Mårten Fernö.
PLoS One, 2016 Mar 10; 11(3). PMID: 26959415    Free PMC article.
How Beneficial is Follow-Up Mammography in Elderly Breast Cancer Survivors?
Kristen P Massimino, Maxine S Jochelson, +2 authors, Monica Morrow.
Ann Surg Oncol, 2016 Jun 17; 23(11). PMID: 27306905    Free PMC article.
Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.
Rikke Langballe, Lene Mellemkjær, +12 authors, Jonine L Bernstein.
Breast Cancer Res, 2016 Jul 13; 18(1). PMID: 27400983    Free PMC article.
Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer.
Jennifer D Brooks, Esther M John, +10 authors, Jonine L Bernstein.
Cancer Med, 2016 Oct 05; 5(11). PMID: 27700016    Free PMC article.
Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
Gretchen L Gierach, Rochelle E Curtis, +7 authors, Amy Berrington de Gonzalez.
JAMA Oncol, 2016 Oct 07; 3(2). PMID: 27711920    Free PMC article.
A model for individualized risk prediction of contralateral breast cancer.
Marzana Chowdhury, David Euhus, +2 authors, Pankaj K Choudhary.
Breast Cancer Res Treat, 2016 Nov 07; 161(1). PMID: 27815748    Free PMC article.
Mammographic breast density is associated with the development of contralateral breast cancer.
Akshara Raghavendra, Arup K Sinha, +9 authors, Carlos H Barcenas.
Cancer, 2017 Jan 31; 123(11). PMID: 28135395    Free PMC article.
ATM, radiation, and the risk of second primary breast cancer.
Jonine L Bernstein, WECARE Study Collaborative Group, Patrick Concannon.
Int J Radiat Biol, 2017 Jun 20; 93(10). PMID: 28627265    Free PMC article.
Review.
Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
Anne S Reiner, Charles F Lynch, +16 authors, WECARE Study Collaborative Group.
Breast Cancer Res, 2017 Jul 21; 19(1). PMID: 28724391    Free PMC article.
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
S Alkner, M-B Jensen, +5 authors, Danish Breast Cancer Cooperative Group.
Breast Cancer Res Treat, 2017 Aug 03; 166(2). PMID: 28766132    Free PMC article.
Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer.
Marzana Chowdhury, David Euhus, +3 authors, Swati Biswas.
Breast Cancer Res Treat, 2018 Mar 08; 170(1). PMID: 29511964    Free PMC article.
Patterns of Occurrence and Outcomes of Contralateral Breast Cancer: Analysis of SEER Data.
Zhenchong Xiong, Lin Yang, +6 authors, Xi Wang.
J Clin Med, 2018 Jun 03; 7(6). PMID: 29857526    Free PMC article.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Streamlining Decision Making in Contralateral Risk-Reducing Mastectomy: Impact of PREDICT and BOADICEA Computations.
Tania Samantha de Silva, Victoria Rose Russell, +8 authors, Daniel Richard Leff.
Ann Surg Oncol, 2018 Jul 19; 25(10). PMID: 30019305    Free PMC article.
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
Jennifer D Brooks, Elizabeth A Comen, +13 authors, Jonine L Bernstein.
Breast Cancer Res, 2018 Dec 12; 20(1). PMID: 30526633    Free PMC article.
Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer.
Gordon P Watt, Anne S Reiner, +23 authors, Jonine L Bernstein.
JAMA Netw Open, 2019 Sep 29; 2(9). PMID: 31560388    Free PMC article.
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Joseph A Sparano, Robert J Gray, +26 authors, George W Sledge.
JAMA Oncol, 2019 Oct 01; 6(3). PMID: 31566680    Free PMC article.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Machine learning on genome-wide association studies to predict the risk of radiation-associated contralateral breast cancer in the WECARE Study.
Sangkyu Lee, Xiaolin Liang, +8 authors, Jung Hun Oh.
PLoS One, 2020 Feb 28; 15(2). PMID: 32106268    Free PMC article.
Second primary breast cancer after unilateral mastectomy alone or with contralateral prophylactic mastectomy.
Shailesh Agarwal, Lisa Pappas, Cindy B Matsen, Jayant P Agarwal.
Cancer Med, 2020 Sep 13; 9(21). PMID: 32918537    Free PMC article.